Drug of Choice in the Management of Hypertension in Diabetes and Diabetic Nephropathy: Angiotensin-Converting Enzyme Inhibitors
Article first published online: 5 APR 2011
© 2011 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 13, Issue 4, pages 285–289, April 2011
How to Cite
Ritz, E. (2011), Drug of Choice in the Management of Hypertension in Diabetes and Diabetic Nephropathy: Angiotensin-Converting Enzyme Inhibitors. The Journal of Clinical Hypertension, 13: 285–289. doi: 10.1111/j.1751-7176.2011.00448.x
- Issue published online: 5 APR 2011
- Article first published online: 5 APR 2011
- Manuscript received January 4, 2011; revised February 1, 2011; accepted February 1, 2011
Hypertension is common in patients with diabetes mellitus and is a main cause of renal and cardiovascular complications. There has been recent controversy on what should be considered the optimal blood pressure goal and the optimal antihypertensive agent. It has become apparent that one blood pressure does not fit all in diabetic patients. Major confounders are preexisting cardiovascular disease and presence or absence of proteinuric kidney disease. In proteinuric diabetic nephropathy, renin-angiotensin system blockade is clearly indicated, but monotherapy is practically always insufficient to achieve target blood pressure values. J Clin Hypertens (Greenwich). 2011;13:285–289. © 2011 Wiley Periodicals, Inc.